Literature DB >> 17921140

Profiling the enzymatic properties and inhibition of human complement factor B.

Giang Thanh Le1, Giovanni Abbenante, David P Fairlie.   

Abstract

Human complement factor B is the crucial catalytic component of the C3 convertase enzyme that activates the alternative pathway of complement-mediated immunity. Although a serine protease in its own right, factor B circulates in human serum as an inactive zymogen and there is a crystal structure only for the inactive state of factor B and various fragments. To provide greater insight to the catalytic function and properties of factor B, we have used short para-nitroanilide derivatives of 4- to 15-residue peptides as substrates to profile the catalytic properties of factor B. Among factors found to influence catalytic activity of factor B was an unusual dependence on pH. Non-physiological alkaline conditions strongly promoted substrate cleavage by factor B, consistent with a pH-accessible conformation of the enzyme that may be critical for catalytic function. Small N-terminal extensions to conventional hexapeptide para-nitroanilide substrates significantly increased catalytic activity of factor B, which was more selective for its cleavage site than trypsin. The new chromogenic assay enabled optimization of catalysis conditions, the profiling of different substrate sequences, and the development of the first reversible and competitive substrate-based inhibitor of factor B. The inhibitor was also shown to prevent in vitro formation of C3a from C3 by factor B, by synthetic and by natural C3 convertase of the alternative complement activation pathway, and to block formation of membrane attack complex. The availability of a reversible substrate-based inhibitor that could stabilize the active conformation of factor B, in conjunction with a pH-promoted higher processing activity, may offer a new avenue to obtain crystal structures of factor B and C3 convertase in an active conformation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17921140     DOI: 10.1074/jbc.M705646200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Proteomic analysis of sera of asymptomatic, early-stage patients with Wilson's disease.

Authors:  Jung-Young Park; Joo Hee Mun; Beom Hee Lee; Sun Hee Heo; Gu-Hwan Kim; Han-Wook Yoo
Journal:  Proteomics Clin Appl       Date:  2009-10       Impact factor: 3.494

Review 2.  Recent developments in low molecular weight complement inhibitors.

Authors:  Hongchang Qu; Daniel Ricklin; John D Lambris
Journal:  Mol Immunol       Date:  2009-10-02       Impact factor: 4.407

3.  Microbe-specific C3b deposition in the horseshoe crab complement system in a C2/factor B-dependent or -independent manner.

Authors:  Keisuke Tagawa; Toyoki Yoshihara; Toshio Shibata; Kazuki Kitazaki; Yuichi Endo; Teizo Fujita; Takumi Koshiba; Shun-ichiro Kawabata
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

Review 4.  Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.

Authors:  József Dobó; Andrea Kocsis; Péter Gál
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

Review 5.  In the Crosshairs: RNA Viruses OR Complement?

Authors:  Nisha Asok Kumar; Umerali Kunnakkadan; Sabu Thomas; John Bernet Johnson
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

6.  Properdin and factor h: opposing players on the alternative complement pathway "see-saw".

Authors:  Lubna Kouser; Munirah Abdul-Aziz; Annapurna Nayak; Cordula M Stover; Robert B Sim; Uday Kishore
Journal:  Front Immunol       Date:  2013-04-23       Impact factor: 7.561

7.  Complement protein levels and MBL2 polymorphisms are associated with dengue and disease severity.

Authors:  Ngo Truong Giang; Hoang van Tong; Do Quyet; Nghiem Xuan Hoan; Trinh Huu Nghia; Nguyen Minh Nam; Hoang Vu Hung; Do Tuan Anh; Can Van Mao; Ho Anh Son; Christian G Meyer; Thirumalaisamy P Velavan; Nguyen Linh Toan
Journal:  Sci Rep       Date:  2020-09-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.